Drugs / Triclabendazole
Triclabendazole
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | EGATEN | — | 2019-02-13 | fda.gov ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04230148 | Feb 2022 → Mar 2026 | fascioliasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01931085 | — | parasitic infectious disease | University of Colorado, Denver | No longer available | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06367361 Comparator | Aug 2026 → Apr 2029 expected | fascioliasis | Universidad Peruana Cayetano Heredia | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-02-13 | Novartis Pharmaceuticals | Regulatory Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease novartis.com ↗
Novartis announced today that the US Food and Drug Administration (FDA) has approved Egaten ® (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-02-13 | Novartis Pharmaceuticals | Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease novartis.com ↗ |
| 2018-07-23 | Novartis Pharmaceuticals | Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke novartis.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triclabendazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01931085 ↗ |
| Known as | EGA230B | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086440 ↗ |
| Known as | Egaten | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086440 ↗ |
| Known as | Egaten tm | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086440 ↗ |
| Known as | Fasinex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086440 ↗ |
| Known as | NSC-759250 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086440 ↗ |
| Known as | NVP-EGA230 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086440 ↗ |
| Known as | Triclabendazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1086440 ↗ |
| Modality | Small molecule | “Triclabendazole is a benzimidazole compound used as a systemic antihelmintic in veterinary practice.” NCT01931085 ↗ |
| Route | Oral | “Both doses were administered orally with food.” NCT04230148 ↗ |